What FDA's shift to continuous AI oversight means for how you architect healthcare agents

Two 2026 regulatory signals are worth designing around if you're building healthcare AI agents, not just reading about after the fact.

Signal one: continuous post-market surveillance, not one-time approval. The FDA is moving AI-enabled devices away from a single approval gate toward ongoing oversight. Architecturally, this means your system needs built-in, exportable evidence of behavior over time — not a one-time validation report. Design the audit trail as a first-class output, not an afterthought bolted on for compliance.

Signal two: clinicians must be able to question the output, not just accept it. Updated Clinical Decision Support guidance requires this explicitly. That's a spec, not a suggestion: every recommendation needs a visible basis (the source/citation), and the interface has to support a real "why did it say that, and do I agree" step — not a black-box output with an accept button.

Context: adoption is real (roughly 80% of hospitals use AI somewhere, though only 22% use domain-specific tools, up from 3% two years ago) and the market is compounding at ~38.62%/year toward $187.69B by 2030. More builders, more scrutiny, both at once.

The design implication is consistent: governed AI agents — grounded, audited, human-checkable by default — aren't just the safer choice, they're increasingly the one the regulatory direction assumes. More at intellibooks.ai/overview.